Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
395 studies found for:    "Chronic myelomonocytic leukemia"
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Adult Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts
Interventions: Drug: Azacitidine;   Drug: Lenalidomide;   Drug: Vorinostat
2 Active, not recruiting Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Revlimid
3 Completed Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
4 Completed
Has Results
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
5 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate
6 Active, not recruiting Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
7 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
8 Active, not recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
9 Active, not recruiting Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myelogenous Leukemia (AML)
Interventions: Drug: Subcutaneous (SC) Azacitidine;   Drug: Oral Azacitidine
10 Completed A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myeloid Leukemia (AML)
Intervention: Drug: Panobinostat
11 Active, not recruiting Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Conditions: Anemia;   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Low to Intermediate-1 MDS
Intervention: Drug: Sotatercept
12 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
13 Terminated Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Conditions: Acute Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: DTGM
14 Completed
Has Results
Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Intervention: Drug: sunitinib malate
15 Recruiting Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: lenzilumab
16 Completed Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: Imatinib
17 Completed Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Conditions: Cancer;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
18 Active, not recruiting MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Leukemia;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Entinostat
19 Recruiting SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)
Conditions: Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Advanced Systemic Mastocytosis;   Advanced Symptomatic Primary Eosinophilic Disorder
Intervention: Drug: SL-401
20 Active, not recruiting
Has Results
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years